Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Guardant Health stock

Own Guardant Health stock in just a few minutes.

Guardant Health, Inc is a diagnostics & research business based in the US. Guardant Health shares (GH) are listed on the NASDAQ and all prices are listed in US Dollars. Guardant Health employs 864 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Guardant Health

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – GH – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Guardant Health share price

Use our graph to track the performance of GH stocks over time.

Guardant Health shares at a glance

Information last updated 2021-04-29.
52-week range$71.41 - $180.83
50-day moving average $150.91
200-day moving average $137.40
Wall St. target price$177.80
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-1.28

Buy Guardant Health shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Stocks, Options, ETFs
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Stocks, ETFs
$0 per month

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Guardant Health stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Guardant Health financials

Revenue TTM $286.7 million
Gross profit TTM $194.2 million
Return on assets TTM -9.48%
Return on equity TTM -22.35%
Profit margin -88.51%
Book value $12.96
Market capitalisation $16.1 billion

TTM: trailing 12 months

Shorting Guardant Health shares

There are currently 5.0 million Guardant Health shares held short by investors – that's known as Guardant Health's "short interest". This figure is 2.7% up from 4.8 million last month.

There are a few different ways that this level of interest in shorting Guardant Health shares can be evaluated.

Guardant Health's "short interest ratio" (SIR)

Guardant Health's "short interest ratio" (SIR) is the quantity of Guardant Health shares currently shorted divided by the average quantity of Guardant Health shares traded daily (recently around 805909.54692557). Guardant Health's SIR currently stands at 6.18. In other words for every 100,000 Guardant Health shares traded daily on the market, roughly 6180 shares are currently held short.

However Guardant Health's short interest can also be evaluated against the total number of Guardant Health shares, or, against the total number of tradable Guardant Health shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Guardant Health's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 Guardant Health shares in existence, roughly 50 shares are currently held short) or 0.0719% of the tradable shares (for every 100,000 tradable Guardant Health shares, roughly 72 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Guardant Health.

Find out more about how you can short Guardant Health stock.

Guardant Health share dividends

We're not expecting Guardant Health to pay a dividend over the next 12 months.

Guardant Health share price volatility

Over the last 12 months, Guardant Health's shares have ranged in value from as little as $71.41 up to $180.83. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Guardant Health's is 0.4896. This would suggest that Guardant Health's shares are less volatile than average (for this exchange).

Guardant Health overview

Guardant Health, Inc. , a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing tests from its LUNAR program for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; LUNAR-2 test for the early detection of cancer in asymptomatic individuals eligible for cancer screening; and GuardantConnect, an integrated software-based solution for clinical and biopharmaceutical customers seeking to connect patients tested with the Guardant360 assay with actionable alterations with potentially relevant clinical trials. In addition, the company offers Guardant Reveal Test for residual disease and recurrence monitoring; Guardant360 tissue genotyping product; and Guardant-19 for use in the detection of the novel coronavirus. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical trial referral, and liquid biopsy testing development and support services to biopharmaceutical companies and medical institutions. Guardant Health, Inc.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site